The role of biomarkers in the early detection of sepsis
16 Jan 2025
Explore how biomarkers can be utilized to aid the early detection of sepsis, in this presentation from the 2024 World Sepsis Congress Spotlight: Unmet Need in Sepsis Diagnosis and Therapy. In this session, discover relevant biomarkers for use in low-resource settings, explore what different clinical phenotypes suggest, find out how a single host biomarker could reduce antibiotics in neonates with suspected LOS (Late-onset sepsis), and much more.
Time stamps for easy viewing:
00:00:00 Introduction
00:01:30 Andrew Argent, University Cape Town, South Africa – Biomarkers of Relevance in Low-Resource Settings 00:14:26 Rita Murri, Gemelli University of Rome, Italy – A Patient is Admitted at the Emergency: What to Do?
00:30:21 Chris Seymour, University of Pittsburgh, USA – Clinical Phenotypes: What Do They Suggest?
00:42:43 Evangelos Giamarellos-Bourboulis, European Sepsis Alliance, Greece – Biomarkers as Endpoints for Treatment Efficacy
00:59:32 Sylvie Pons, Joint Research Unit, Hospices Civils de Lyon, bioMérieux, France – Reducing Antibiotics With a Single Host Biomarker in Neonates Suspected of LOS: The EMERAUDE Study
About the company
Global Sepsis Alliance
The Global Sepsis Alliance (GSA) is a non-profit charity organization with the mission to provide global leadership to reduce the worldwide burden of sepsis. The GSA is the initiator of World Sepsis Day on September 13 and World Sepsis Congress, a series of free online congresses bringing knowledge about sepsis to all parts of the world, among other initiatives.
The GSA works closely with its over 120 member organizations from all over the world – patient advocacy groups, professional societies, healthcare authorities, and governments – to implement changes on how sepsis is prioritized, diagnosed, and treated all around the world, as laid out in the WHO Resolution on Sepsis.
